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The world of cancer research is abuzz with talk of the MYC family of transcription factor genes. The 
reason is simple. Because these genes regulate the expression of more than 15 percent of all 
human genes and carry out essential functions in proliferative tissues, their mis-regulation can drive 
a wide variety of cancers. For example, MYConcogenes are associated with poor prognosis in 
breast, prostate and colon cancers. In addition, over-expression of one member of the gene 
family, c-MYC, is routinely found in a high proportion of ovarian, liver and lung cancers, and aberrant 
expression of N-MYC, another family member, contributes to pediatric neuroblastoma, the most 
common cancer afflicting infants. Clearly, a successful strategy to target MYC-driven cancers could 
have revolutionary implications for significant populations of cancer patients. Unfortunately, the 
solution is far from simple. MYC oncogene family members are considered "undruggable" for two 
reasons. First, MYC genes encode basic helix loop helix transcription factors (see figure), which do 
not possess druggable domains. Second, because MYC-encoded transcription factors carry out so 
many functions, their prolonged down-regulation would likely result in severe side effects for 
patients. 
To tackle this problem, first author Dr. Masafumi Toyoshima, principal investigator Dr. Carla Grandori 
(both of the Human Biology Division) and several colleagues recently set out to identify synthetic 
lethal interactions with c-MYC over-expression, which could potentially contribute to the treatment 
of c-MYC-driven cancers. Synthetic lethality occurs when mutations in two genes lead to cell death. 
For Toyoshima and co-authors, the core mutational effect of interest was c-MYCover-expression, 
and the desired endpoint involving cell death eventually would be the demise of cancer cells. The 
primary goal of the research team was to identify the candidate synthetic lethal interaction partners 
with c-MYC aberrant expression, the knockdown of which would avoid the highly toxic side effects of 
directly targeting c-MYC itself. 
In the first stage of their successful functional genomics pipeline, Toyoshima et al. used a high-
throughput siRNA screen involving the knockdown of each of 3,300 genes already known to be part 
of the druggable genome. They searched for toxic effects on human foreskin fibroblast cells, in 
which they induced c-MYC over-expression using a retroviral expression vector. This led to the 
identification of 148 candidate synthetic lethal genes. Next, the authors refined their search by 
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selecting smaller and smaller subsets of candidate genes based on a number of considerations, 
including: predicted druggability, involvement in cancer pathways, potential side-effects, confirmation 
of DNA damage and availability of pharmacological inhibitors. Taken together, these criteria 
narrowed the authors' search to several good candidates for potential use in fighting MYC-driven 
neuroblastoma. The research team focused on one of the candidates (casein kinase 1 
epsilon, CSNK1e), for which a promising drug had already been developed. Toyoshima et al. then 
demonstrated thatCSNK1e expression correlates with N-MYC amplification in neuroblastoma. In the 
next step of their screening pipeline, the authors arrived at successful preclinical validation. Using 
RNAi and small molecule inhibitors, Toyoshima et al. confirmed that inhibition of CSNK1e halted the 
growth of N-MYC-driven neuroblastoma tumors in mice. Finally, the authors conducted a meta-
analysis of human microarray datasets. This revealed that CSNK1e expression is positively 
associated with N-MYCamplification in human primary neuroblastoma cells and with poor prognosis 
for this type of cancer. The meta-analysis further showed that CSNK1e expression is statistically 
associated with c-MYC amplification in colon, lung and breast cancers in adults. 
In a single impressive body of work, Toyoshima et al. identified CSNK1e as a promising therapeutic 
target for certain MYC-driven cancers. Moreover, their high-throughput functional genomics pipeline 
also uncovered a rich therapeutic space of other synthetic lethal targets for potentially treating MYC-
driven cancer. Of broader significance, the authors demonstrated the future effectiveness of their 
approach in screening possible therapeutic targets for other oncogenes that were once considered 
to be undruggable. 
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Image downloaded (with permission) 
from Wikimedia Commons 
X-ray crystallographic structures of the 
basic/helix-loop-helix/leucine zipper 
domains of the c-MYC (red) and MAX 
(blue) heterodimer bound to its DNA 
target (the E box hexanucleotide, 5'-
CACGTG-3'). 
